ImExHS (IME) Q3 2026 TU earnings summary

Executive summary

• Q3 FY26 revenue was $8.9m, up 23% YoY reported and 6% on a constant-currency basis; YTD revenue was $24.8m, up 19% reported and 11% constant currency.

• Q3 underlying EBITDA was $0.6m, in line with pcp; YTD underlying EBITDA rose to $1.9m from $0.9m.

• Radiology Services performed ahead of plan, while software bookings were below plan and software ARR was flat during the quarter.

Financial highlights

• Software revenue was $2.9m in Q3, the highest quarterly figure in FY26; Q3 software NARR was $282,928 across 13 new contracts, with YTD NARR of $1.37m.

• Q3 customer receipts were $9.2m; net operating cash inflow was $1.0m, with cash at $2.5m at 30 September 2026 versus $2.0m at 30 June.

• Cash used in investing was $0.3m, including $0.2m capitalised software; financing cash outflow was $0.1m, reducing debt to $0.17m.

Outlook and guidance

• FY26 guidance was reconfirmed: revenue of $31.4m–$33.7m, up 8%–16% YoY, and underlying EBITDA of $2.4m–$2.7m, up 48%–66%.

• Q4 priorities include converting deferred partner-led closures, contracted software ARR not yet billing, and an expanding qualified opportunity base into repeatable sales.

• $2.4m of contracted software not yet billing went live in Q3 and is expected to ramp toward estimates; the remaining $2m is being progressed.